Abstract
We report the case of a young woman affected by hypothyroidism due to Hashimoto’s thyroiditis, previously well compensated with a full replacement therapy (150 mcg/day of levothyroxine), presenting a clinical picture of myxedema, with a TSH=650 mU/L. Two years earlier she had started a dialysis treatment because of a chronic renal failure and had been under treatment for the last 18 months with sevelamer carbonate, a phosphate binder. No improvement of clinical conditions nor reduction in TSH serum levels was observed even on increasing the dose of levothyroxine up to 300 mcg/day, whereas euthyroidism finally restored by administering the first morning dose of sevelamer carbonate at least 4 hours after levothyroxine administration. This case shows that sevelamer carbonate, in analogy with what has been already reported for sevelamer hydrochloride, can interfere with levothyroxine absorption leading to a condition of hypothyroidism in patients previously well compensated with a given replacement dose.
Keywords: Dialysis, hyperphosphataemia, hypothyroidism, intestinal absorption, levothyroxine, phosphate binder, sevelamer carbonate.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Sevelamer Carbonate Markedly Reduces Levothyroxine Absorption
Volume: 14 Issue: 3
Author(s): Michele Iovino, Nicola Iovine, Alfanso Petrosino, Vito A. Giagulli, Brunella Licchelli, Edoardo Guastamacchia and Vincenzo Triggiani
Affiliation:
Keywords: Dialysis, hyperphosphataemia, hypothyroidism, intestinal absorption, levothyroxine, phosphate binder, sevelamer carbonate.
Abstract: We report the case of a young woman affected by hypothyroidism due to Hashimoto’s thyroiditis, previously well compensated with a full replacement therapy (150 mcg/day of levothyroxine), presenting a clinical picture of myxedema, with a TSH=650 mU/L. Two years earlier she had started a dialysis treatment because of a chronic renal failure and had been under treatment for the last 18 months with sevelamer carbonate, a phosphate binder. No improvement of clinical conditions nor reduction in TSH serum levels was observed even on increasing the dose of levothyroxine up to 300 mcg/day, whereas euthyroidism finally restored by administering the first morning dose of sevelamer carbonate at least 4 hours after levothyroxine administration. This case shows that sevelamer carbonate, in analogy with what has been already reported for sevelamer hydrochloride, can interfere with levothyroxine absorption leading to a condition of hypothyroidism in patients previously well compensated with a given replacement dose.
Export Options
About this article
Cite this article as:
Iovino Michele, Iovine Nicola, Petrosino Alfanso, Giagulli A. Vito, Licchelli Brunella, Guastamacchia Edoardo and Triggiani Vincenzo, Sevelamer Carbonate Markedly Reduces Levothyroxine Absorption, Endocrine, Metabolic & Immune Disorders - Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871530314666140902151804
DOI https://dx.doi.org/10.2174/1871530314666140902151804 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism
Current Nutrition & Food Science The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Current Hydrogel Solutions for Repairing and Regeneration of Complex Tissues
Current Medicinal Chemistry Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Current Topics in Medicinal Chemistry Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Action of Anti-HIV Drugs and Resistance: Reverse Transcriptase Inhibitors and Protease Inhibitors
Current Pharmaceutical Design Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Malnutrition could Predict 3-month Functional Prognosis in Mild Stroke Patients: Findings from a Nationwide Stroke Registry
Current Neurovascular Research Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Nanocrystals as Effective Delivery Systems of Poorly Water-soluble Natural Molecules
Current Medicinal Chemistry A Proteomic Analysis of the Virulence Factors of Three Common Bacterial Species Involved in Periodontitis and Consequent Possible Atherosclerosis: A Narrative Review
Current Protein & Peptide Science A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer’s Disease
Current Drug Targets A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Targeting Phosphatidylserine in Anti-Cancer Therapy
Current Pharmaceutical Design Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Current Cancer Therapy Reviews Analysis of Chemical Composition by GC-MS and In-vitro Antidiabetic Activity of Azadirachta Indica Leaves Collected from Erbil, Iraq
Current Traditional Medicine